|
gptkbp:instance_of
|
gptkb:Company
|
|
gptkbp:bfsLayer
|
4
|
|
gptkbp:bfsParent
|
gptkb:Neurocrine_Biosciences
|
|
gptkbp:acquisition
|
gptkb:Neuro_Rx
|
|
gptkbp:awards
|
best workplace awards
biopharma innovation awards
clinical trial excellence awards
|
|
gptkbp:clinical_trial
|
gptkb:historical_event
gptkb:Company
gptkb:psychologist
Phase 1
Phase 2
Phase 3
postpartum depression
|
|
gptkbp:collaborations
|
gptkb:Harvard_University
gptkb:Massachusetts_Institute_of_Technology
gptkb:Stanford_University
academic institutions
|
|
gptkbp:community_engagement
|
patient advocacy groups
mental health organizations
research consortia
|
|
gptkbp:financial_products
|
gptkb:Company
|
|
gptkbp:focus
|
central nervous system disorders
|
|
gptkbp:founded
|
gptkb:2010
|
|
gptkbp:founder
|
Jeffrey Jonas
|
|
gptkbp:headquarters
|
gptkb:Cambridge,_Massachusetts
|
|
gptkbp:healthcare
|
gptkb:Zulresso
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Sage Therapeutics
|
|
gptkbp:investment
|
gptkb:Company
|
|
gptkbp:language_of_instruction
|
gptkb:SAGE-689
gptkb:SAGE-718
SAGE-553
|
|
gptkbp:leadership
|
gptkb:David_A._H._Hsu
Katherine A. H. Hsu
Barry Greene
|
|
gptkbp:market_cap
|
approximately $1 billion
|
|
gptkbp:partnership
|
gptkb:Eli_Lilly
gptkb:Biogen
|
|
gptkbp:products
|
gptkb:SAGE-217
gptkb:Zulresso
SAGE-324
|
|
gptkbp:publishes
|
peer-reviewed journals
clinical research
preclinical studies
|
|
gptkbp:research_areas
|
neurology
psychiatry
GABA receptor modulation
glutamate modulation
neuroactive steroids
|
|
gptkbp:research_focus
|
gptkb:psychologist
neuropsychiatric disorders
|
|
gptkbp:stock_exchange
|
gptkb:NASDAQ
|
|
gptkbp:symbol
|
gptkb:SAGE
|
|
gptkbp:website
|
www.sagerx.com
|